Admedus and Genpharm receive approval to market CardioCel in UAE

21 November 2016 (Last Updated November 21st, 2016 18:30)

Australian healthcare group Admedus and UAE-based pharmaceutical company Genpharm have obtained approval to market CardioCel in UAE.

Australian healthcare group Admedus and UAE-based pharmaceutical company Genpharm have obtained approval to market CardioCel in UAE.

CardioCel is a single-ply bio scaffold that has been designed to remain functional, durable and free from calcification.

Genpharm managing partner Karim Smaira said: “This is an important product approval for both cardiac surgeons and their patients in the UAE and beyond.

"This is an important product approval for both cardiac surgeons and their patients in the UAE and beyond."

“Bringing cutting edge medical products to the MENA region is one of our primary goals and we are delighted, therefore, to announce the approval of CardioCel in the region.”

Based on Admedus’ proprietary ADAPT tissue engineering process, application of CardioCel pericardial closure and to repair cardiac and vascular defects including intracardiac defects; septal defects; valve and annulus repair; great vessel reconstruction, peripheral vascular reconstruction and suture line buttressing. with no calcification observed after being implanted for eight years.

The bio-scaffold features flexibility and elasticity in its design which makes it easy to use. Its tensile strength also makes the scaffold suitable to be used in pressured environments like valves and also is effective in preventing suture line bleeding.

Admedus chairman and interim CEO Wayne Paterson said: “As we continue to drive strong sales growth of CardioCel, this approval is a significant milestone in terms of our expansion of the product franchise across emerging markets.

“The UAE is a strategically important location as a central hub in MENA for performing cardiovascular surgery.”

Cardiocel was recently approved in Kuwait.